<div id="readability-page-1"><div>Early Warning News Release Regarding the Issuance of Securities of ZYUS Life Sciences Corporation This press release is issued pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES On April 14, 2025, Mr. Wayne Brownlee (the &#34;Acquiror&#34;), who serves as a director of ZYUS Life Sciences Corporation (the “Company”) acquired control and direction over an additional 4,875,000 common share purchase warrants (the “Warrants”) in the capital of the Company (TSXV: ZYUS) in connection with the issuance and amendment of certain unsecured loans advanced to the Company (the “Warrant Issuance”). The Warrants have an expiry date of March 28, 2027 and an exercise price of $0.80 per common share. As a result of the Warrant Issuance, the Acquiror owns and controls an additional 4,875,000 common share purchase warrants, representing approximately 6.56% of the Company’s issued and outstanding common shares as of the closing date of the Acquisition. Prior to the Acquisition, the Acquiror owned and controlled 3,780,943 common shares (“Common Shares”) of the Company and 526,315 Common Share purchase warrants (the “Prior Warrants”), representing approximately 5.08% of the issued and outstanding Common Shares on a non-diluted basis and 5.79% on a partially diluted basis, assuming exercise of such Prior Warrants. The Prior Warrants have an expiry date of August 26, 2026 and exercise price of $1.30 per Common Share. Following the Acquisition, the Acquiror owns or controls 3,780,943 Common Shares and 5,401,315 warrants, representing 5.08% of the issued and outstanding Common Shares on a non-diluted basis and 12.35% on a partially diluted basis, assuming exercise of such Warrants. The Acquiror acquired the Warrants for investment purposes and has a long‐term view of the investment. The Acquiror intends to review its investment in the Company on a continuing basis and may, from time to time, increase or decrease its beneficial ownership, control, direction or economic exposure over securities of the Company either on the open market or through private acquisitions in the future depending on market conditions, reformulation of plans and/or other relevant factors and subject to applicable securities laws. The Acquiror may, from time to time and at any time, acquire additional securities and/or other equity, debt or other securities or instruments of the Company in the open market or otherwise, and reserves the right to dispose of any or all of the securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities, the whole depending on market conditions, the business and prospects of the Company and other relevant factors, including compliance with applicable securities laws. An early warning report has been filed by the Acquiror under applicable securities laws and will be available on the Company’s SEDAR+ profile at www.sedarplus.ca. For more information, please contact the Acquiror at 204-407 Downey Road, Saskatoon, SK S7N 4L8; telephone: (306) 242-2357 <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA0MTQwMDcxODNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA0MTQwMDcxODNyMQ"/> (306) 242-2357 View source version on businesswire.com: https://www.businesswire.com/news/home/20250414007183/en/</div></div>

2025 年 4 月 14 日，ZYUS 生命科学公司董事 Wayne Brownlee 获得了 4,875,000 个普通股认购权证，使他的控制权在部分稀释基础上增加至 12.35%。这些认购权证的到期日为 2027 年 3 月 28 日，行使价格为 0.80 美元，系与公司无担保贷款相关获得。Brownlee 打算审查他的投资，并可能根据市场情况调整他的持股。早期警示报告已提交，并可在公司的 SEDAR+ 档案中查阅

关于 ZYUS 生命科学公司证券发行的预警新闻发布